Tough At The Top: Raj Denhoy On The Drive For Growth In A Maturing Medtech Industry
Executive Summary
The medical technology industry was a solid if tricky bet for investors in 2017, and will be so in 2018. That is the view of Jefferies Healthcare US-based equity analyst Raj Denhoy. Speaking to In Vivo during the group's London meeting in fall 2017, he gave context to the motivations and drivers of medtechs large and small for 2018 and beyond.
You may also be interested in...
AI Medical Imaging And Radiotherapy First For UK’s NICE
Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.
AI Medical Imaging And Radiotherapy First For UK’s NICE
Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.
CMR Surgical Targeting New RAS Procedures And Markets For Growth
Marcio Coelho, chief commercial officer of robotic assisted surgery company CMR Surgical, updated In Vivo on the company’s unique approach to expanding uptake of its technologies in global markets, including those that are underserved in RAS devices.